Caliber Biotherapeutics and iBio establish agreement to develop biopharmaceuticals
The agreement will combine iBio's proprietary iBioLaunch technology and Caliber's proprietary plant-based manufacturing capabilities. While the agreement will first focus on developing an undisclosed monoclonal antibody for oncology indications, it will also allow for an extraordinary surge capacity for biotherapeutics and vaccines against bioterrorism and pandemic disease.
"This combination is a major advance for recombinant biopharmaceuticals," Robert B. Kay, the executive chairman and CEO of iBio, said. "By bringing together our intellectual property, facilities, and know-how, we not only will accelerate and improve development of our own product pipelines, but also enable third-party developers and sponsors to access turn-key solutions for their product candidates through licenses and partnerships with us."
Under the terms of the agreement, iBio will receive milestone and license fees for developing product targets selected by Caliber. Caliber will be responsible for funding commercialization and clinical development of collaboration products. iBio will get royalties on product sales and other revenues.
"This new collaboration with iBio enables us to develop products addressing important unmet medical needs that uniquely benefit from Nicotiana benthamiana plant-based expression technology," Rahul Singhvi, Caliber's managing director, said. "The combination of iBio's state-of-the-art expression technology and Caliber's innovative manufacturing infrastructure makes the promise of plant-based pharmaceuticals very real. We are excited about combining our joint capabilities to create valuable products that would otherwise be commercially impossible to produce or develop."
The companies did not disclose detailed financial terms of the agreement.